Literature DB >> 17688172

Biochemical markers, extracellular components in liver fibrosis and cirrhosis.

D M Bolarin1, E C Azinge.   

Abstract

Liver fibrosis and cirrhosis are common sequelae to diverse liver injuries in the tropics or Nigeria. The development of hepatic fibrosis or cirrhosis is due to increased synthesis, deposition, and possibly reduced degradation of hepatic extracellular matrix components, especially collagens, such as interstitial type I and III, basement membrane type IV, microfibrillar type VI, and pericellular type V, non-collagenous proteins, such as laminin, fibronectin, undulin, etc., and various types of proteoglycans, such as hyaluronan, etc. In Nigeria, the common approach for diagnosing or assessing the activity of connective tissue in this organ is the histological examination of a biopsy, if one is performed by a specialist physician. The liver biopsy provides a static picture of the changes that have already taken place in the liver. Another possible method is (where the facilities are available) a quantitative assessment of the liver biopsy by biochemical determination of total collagen via hydroxyproline. Biopsy is an invasive method and cannot be repeated often enough in the bid to ensuring an intensive follow-up of the changes taking place during the course of antifibrotic treatment or therapy. Thus, serum or other biological fluid assays for connective tissue proteins, such as the aminoterminal propeptide of type III Procollagen PIIINP, or the dimeric carboxyterminal domain of type IV collagen known as NCl or PIVCP, laminin, and others are essentially non-invasive and can be carried out repeatedly. In addition, the measurement of certain enzymes of connective tissue proteins in serum may the reflect activity of liver fibrogenesis. They offer the potential for diagnosis and therapeutic control. However, it is very important to note that circulating biochemical markers of fibrogenesis, fibrolysis or both may not reflect hepatic fibrosis or cirrhosis, since they are not liver-specific. Thus, the best diagnostic approach would be the identification and measurement in serum of the driving force of fibrogenic process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17688172     DOI: 10.4314/nqjhm.v17i1.12541

Source DB:  PubMed          Journal:  Nig Q J Hosp Med        ISSN: 0189-2657


  10 in total

Review 1.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

2.  Chunggan extract, a traditional herbal formula, ameliorated alcohol-induced hepatic injury in rat model.

Authors:  Hyeong-Geug Kim; Jung-Min Kim; Jong-Min Han; Jin-Seok Lee; Min-Kyung Choi; Dong-Soo Lee; Yeon-Hwa Park; Chang-Gue Son
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  Evaluation of the utility of serum prolidase as a marker for liver fibrosis.

Authors:  John C Stanfliet; Michael Locketz; Peter Berman; Tahir S Pillay
Journal:  J Clin Lab Anal       Date:  2014-05-05       Impact factor: 2.352

4.  Role of urinary biomarkers of N,N-dimethylformamide in the early detection of hepatic injury among occupational exposed workers.

Authors:  Jun He; Pei Wang; Jian-quan Zhu; Gang Wu; Jun-min Ji; Ya Xue
Journal:  Int Arch Occup Environ Health       Date:  2010-02-12       Impact factor: 3.015

5.  Effect of Huazhuojiedu medicated serum on the proliferation and activation of hepatic stellate cells and the expression of PI3K and p-Akt in rats.

Authors:  Liang Kang; Yangang Wang; Mingxi Zhang; Runxue Sun; Yingying Lou; Ying Wang; Diangui Li
Journal:  Int J Clin Exp Med       Date:  2014-10-15

6.  Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis.

Authors:  Huseyin Kayadibi; Mustafa Gültepe; Bulent Yasar; Ali T Ince; Omer Ozcan; Osman M Ipcioglu; Oya O Kurdas; Burhanettin Bolat; Yusuf Z Benek; Hakan Guveli; Sacide Atalay; Selvinaz Ozkara; Ozcan Keskin
Journal:  Dig Dis Sci       Date:  2008-11-07       Impact factor: 3.199

7.  Does prolidase indicate worsening of hepatitis B infection?

Authors:  Fazilet Duygu; Nurten Aksoy; Aysegul Copur Cicek; Ilknur Butun; Sebnem Unlu
Journal:  J Clin Lab Anal       Date:  2013-09       Impact factor: 2.352

8.  Clinical Benefits of Biochemical Markers of Fibrosis in Egyptian Children With Chronic Liver Diseases.

Authors:  Tawhida Y Abdel-Ghaffar; Behairy E Behairy; Azza Abd El-Shaheed; Karam Mahdy; Mohamed El-Batanony; Mohsen H Hussein; Mostafa M Sira
Journal:  Gastroenterology Res       Date:  2010-11-20

9.  Correlation between Tgf-Β1 and Fsp-1 Expression in Chronic Viral Hepatitis - an Immunohistochemical Study.

Authors:  D E Tache; Ş G Firu; A M Andrei; A Predescu; Ş O Purcaru; A M Dobrescu; A Dricu; C G Pisoschi; E C Stănciulescu
Journal:  Curr Health Sci J       Date:  2015-04-10

10.  Extracellular Water to Total Body Water Ratio in Viral Liver Diseases: A Study Using Bioimpedance Analysis.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Noriko Ishii; Yoshinori Iwata; Chikage Nakano; Ryo Takata; Takashi Nishimura; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Kunihiro Hasegawa; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Nutrients       Date:  2018-08-12       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.